Episode 3 - REGENCY TRIAL - LUPUS NEPHRITIS
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Episode 3 - REGENCY TRIAL - LUPUS NEPHRITIS
-
Narrated by:
-
Written by:
About this listen
The REGENCY Trial evaluates Obinutuzumab, a type II anti-CD20 monoclonal antibody, in Class III and IV Lupus Nephritis (LN). This episode dives into:
- The mechanism of B-cell depletion therapy in lupus nephritis
- Study results comparing Obinutuzumab + standard therapy vs. standard therapy alone
- Effects on renal response, proteinuria reduction, and steroid-sparing benefits
- The future role of targeted biologics in lupus nephritis treatment
adbl_web_anon_alc_button_suppression_c
No reviews yet